Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.

29 May 2020

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers say the drug should be tested in a larger study to further determine its safety and efficacy as a potential disease-modifying strategy.

29 May 2020

Combination therapy found to be effective against IDH1-mutated acute myeloid leukemia

A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was found to be effective against a specific genetic subtype of acute myeloid leukemia (AML) in a Phase Ib/II trial led by researchers at The University of Texas MD Anderson Cancer Center.

28 May 2020

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.

18 May 2020

Scientists develop new method to synthesize cotylenin A

Scientists at Waseda University succeeded in developing a method for a total synthesis of cotylenin A, a plant growth regulator which has attracted considerable attention from the scientific community due to its promising bioactivity as an anti-cancer agent.

13 May 2020

Indiana researchers identify new target for colorectal cancer immunotherapy

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

11 May 2020

More selective elimination of leukemic and hematopoietic stem cells

Acute myeloid leukemia is an aggressive cancer of the blood-forming system. It affects the hematopoietic stem cells, or blood stem cells, of various white blood cells and of the red blood cells and platelets.

8 May 2020

Kurome secures license to develop novel therapies for chemo-resistant cancer

Seed investor CincyTech announced the formation of Kurome Therapeutics ("Kurome"), a preclinical stage company developing novel therapies targeting cancer cells' adaptive resistance mechanisms beginning with hematopoietic, or blood cell, cancers.

29 Apr 2020

Using genome-wide CRISPR technology to identify leukemia's weakness

A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse.

20 Apr 2020

OGT delivers translocation and partial tandem duplication detection with updates to SureSeq NGS portfolio

Oxford Gene Technology announces the addition of accurate detection capabilities for translocations and difficult-to-sequence partial tandem duplications.

From Oxford Gene Technology 7 Apr 2020

Roscovitine enhances nuclear enrichment of traditionally cytoplasmic signaling molecules

Oncotarget Volume 11, Issue 12 reported that using the HL-60 human non-APL AML model where ATRA causes nuclear enrichment of c-Raf that drives differentiation/G0-arrest, the research team now observe that roscovitine enhanced nuclear enrichment of certain traditionally cytoplasmic signaling molecules and enhanced differentiation and cell cycle arrest.

26 Mar 2020

Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor

Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.

21 Mar 2020

Scientists receive €2.45 million funding for leukemia research

Leukemia stem cells are considered to be the starting point of leukemia; their elimination is a basic prerequisite for a successful long-term therapy. Scientists at Heidelberg University Hospital, the Heidelberg Institute for Stem Cell Technology and Experimental Medicine at the German Cancer Research Center, the German Cancer Research Center and the European Molecular Biology Laboratory have now obtained research funding of €2.45 million from the German Federal Ministry of Education and Research as part of the junior research alliance LeukoSyStem.

11 Mar 2020

New 'Immuno-Engineering to Improve Immunotherapy' Center formed to advance cancer therapy

Harvard University's Wyss Institute of Biologically Inspired Engineering and its collaborating institutions, the Harvard John A. Paulson School of Engineering and Applied Sciences, Dana-Farber Cancer Institute, and Harvard's Department of Stem Cell and Regenerative Biology, announce the formation of a new NIH-funded Immuno-Engineering to Improve Immunotherapy Center.

7 Mar 2020

New clinical trial uses universal natural killer cell approach to treat acute myeloid leukemia

A new, phase I clinical trial offered The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute will treat patients with relapsed or refractory acute myeloid leukemia using a novel universal natural killer cell approach.

27 Feb 2020

Myeloid Leukemia News and Research

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

Combination therapy found to be effective against IDH1-mutated acute myeloid leukemia

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Scientists develop new method to synthesize cotylenin A

Indiana researchers identify new target for colorectal cancer immunotherapy

More selective elimination of leukemic and hematopoietic stem cells

Kurome secures license to develop novel therapies for chemo-resistant cancer

Using genome-wide CRISPR technology to identify leukemia's weakness

OGT delivers translocation and partial tandem duplication detection with updates to SureSeq NGS portfolio

Roscovitine enhances nuclear enrichment of traditionally cytoplasmic signaling molecules

Preclinical study characterizes the binding affinity and selectivity of a selective FLT3 inhibitor

Scientists receive €2.45 million funding for leukemia research

New 'Immuno-Engineering to Improve Immunotherapy' Center formed to advance cancer therapy

New clinical trial uses universal natural killer cell approach to treat acute myeloid leukemia

Breakthrough discovery could open up new treatments for some blood cancers

Smoking cessation goody bag helps people quit smoking

New research could lead to 'breakthrough' for myelodysplastic syndrome

Inexpensive drug may be used to counteract treatment resistance in patients with leukemia

Harmful genetic mutations in healthy donors' stem cells may create problems in AML patients

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News